1
|
Onitilo AA, Kar P, Engel JM, Glurich I. Long-term cardiac and vascular disease outcomes following adjuvant tamoxifen therapy: current understanding of impact on physiology and overall survival. Minerva Med 2013; 104:141-153. [PMID: 23514990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The relative impact of tamoxifen therapy in women with breast cancer on overall survival, especially as it pertains to cardiac and cardiovascular outcomes, remains under debate in the literature. This review focuses specifically on outcomes of studies that examined large clinical trials with longest duration in patient follow-up relative to these parameters in which compliance with therapy could be documented. Over time, evidence supports potential cardioprotective effects and capacity of adjuvant therapy to improve lipid profiles in women treated with tamoxifen. While some benefit to cardiac health is supported, outcomes related to cardiovascular events remain variable across studies and challenging to interpret. In summary, overall survival in women treated with tamoxifen over time has increasingly shown a trend towards positive outcomes in the context of evaluation of post-treatment cardiac and vascular health. Potential mechanisms underlying the cardioprotective effects of tamoxifen are briefly discussed.
Collapse
Affiliation(s)
- A A Onitilo
- Department of Hematology/Oncology, Marshfield Clinic Weston Center, Weston, WI 54476, USA.
| | | | | | | |
Collapse
|
2
|
Rocque GB, Onitilo AA, Engel JM, Pettke EN, Boshoven AM, Zhang S, Kim KM, Rishi S, Waack B, Wisinski KB, Tevaarwerk AJ, Burkard ME. P5-18-12: Perception, Practice and Toxicity of Adjuvant Treatment of HER2+ Breast Cancer in Wisconsin. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-18-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
INTRODUCTION: Multiple trastuzumab-containing (neo)adjuvant regimens are used for HER2+ BrCa, but the experience with these regimens in routine practice is not reported. Some oncologists select TCH based on BCIRG 006, whereas others prefer anthracycline-based therapy. We evaluated whether oncologists’ perceptions of these regimens match clinical experience.
METHODS: We surveyed 151 Wisconsin (WI) oncologists regarding factors impacting selection of TCH versus AC-TH; 65 (42%) responded. At the same time, we reviewed 200 cases of HER2+ BrCa treated with adjuvant trastuzumab from 2003 to 2010 at the University of Wisconsin Carbone Cancer Center (UW) and the Marshfield Clinic. We collected baseline patient and tumor characteristics, regimen administered, and toxicities as assessed by lab values, cardiac ejection fraction (EF), hospitalizations, dose reductions/delays, and ability to complete therapy.
RESULTS: Two-thirds of surveyed oncologists prefer anthracycline-based therapy over TCH. Of oncologists preferring TCH, 20 of 23 had been in practice for >10 years. Oncologists perceived that AC-TH and TCH were equally likely to be completed. The majority of physicians select therapy based on patient age and stage, with a preference for AC-TH for node-positive disease and TCH for early stage (T1a-bN0) tumors. Despite BCIRG 006 remaining unpublished at the time of the survey, peer-review publication was cited as the most important factor in selecting this regimen. Although use of granulocyte colony stimulating factor (GCSF) in BCIRG 006 has not reported, 50% of oncologists indicated routine use with cycle 1 of TCH. Of the 200 cases reviewed, 114 women received AC-TH, 48 women received TCH, and 38 had other regimens. The median age was 53 years old, 52% had node positive disease. Acute toxicity trended higher with TCH. For example, there were fewer dose modifications/delays for AC-TH than TCH (31% vs. 46%, p=0.07). This may have been due to common use of GCSF with AC-TH (77% vs. 33% use with TCH). Neutropenic fever (NF) was higher with TCH, reaching 25% incidence when administered without GCSF. However, NF did not occur in the 8 TCH patients who received cycle 1 GCSF. There was no correlation between NF and patient age. The incidence of left ventricular EF decline leading to cessation of trastuzumab was similar for both regimens (19.4% AC-TH vs. 14.6% TCH; p = 0.64). Trastuzumab was completed as planned in 70% of patients. Although EF decline was most common explanation, 13% of early trastuzumab discontinuations occurred for other reasons.
CONCLUSION: TCH and AC-TH are the most commonly administered adjuvant regimens for WI women with HER2+ BrCa. Amongst WI oncologists, TCH is perceived as safer, but is less likely to be recommended for node-positive BrCa. This retrospective analysis suggests that acute myelosuppression is greater for TCH, with a significant rate of NF. Per ASCO guidelines, these data suggest GCSF should be used routinely with TCH due to high rate of FN. We were intrigued that oncologists who have been in practice longer are more likely to choose TCH. The reasons for this are unclear, but are perhaps related to prior experience with long-term cardiotoxicity with AC-TH.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-18-12.
Collapse
Affiliation(s)
- GB Rocque
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - AA Onitilo
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - JM Engel
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - EN Pettke
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - AM Boshoven
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - S Zhang
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - KM Kim
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - S Rishi
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - B Waack
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - KB Wisinski
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - AJ Tevaarwerk
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - ME Burkard
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| |
Collapse
|
3
|
Onitilo AA, Engel JM, Sajjad SM. The possible role of hemochromatosis in testicular cancer. Med Hypotheses 2011; 77:179-81. [PMID: 21549511 DOI: 10.1016/j.mehy.2011.04.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2010] [Revised: 03/10/2011] [Accepted: 04/04/2011] [Indexed: 11/28/2022]
Abstract
Hemochromatosis is a genetic disorder of iron metabolism that results in elevated iron absorption in the intestines, which leads to progressive iron accumulation in a variety of organs. Studies have shown that excessive iron deposits in the liver due to hereditary hemochromatosis leads to cirrhosis, which can put an individual at increased risk for developing hepatocellular carcinoma. Testicular atrophy, sometimes caused by excessive iron deposition in the testes, is a risk factor for testicular cancer. Therefore, the possible role of hereditary hemochromatosis in testicular cancer is explored.
Collapse
Affiliation(s)
- A A Onitilo
- Marshfield Clinic, Department of Hematology/Oncology, Weston Center, 3501 Cranberry Boulevard, Weston, WI 54476, USA.
| | | | | |
Collapse
|
6
|
Abstract
We report an isolated pancreas transplant recipient on immunosuppressive therapy with parvovirus B19 infection. He presented with a chronic transfusion-dependent anemia, unresponsive to erythropoietin therapy. Bone marrow cytomorphology was highly suggestive of parvovirus pure red cell aplasia, which was confirmed with polymerase chain reaction positive for parvovirus B19 DNA from peripheral blood. The anemia responded briskly and reticulocyte counts improved from 0.0% to 17.0% within 1 week after the administration of intravenous immunoglobulin. We discuss the difficulty of serological diagnosis in such cases, the importance of using techniques that directly identify the virus, and taking measures that may prevent recurrence.
Collapse
Affiliation(s)
- A A Onitilo
- Department of Hematology/Oncology, Marshfield Clinic-Wausau Center, Wausau, Wisconsin 54401, USA.
| | | |
Collapse
|
7
|
Onitilo AA, Lin YH, Okonofua EC, Afrin LB, Ariail J, Tilley BC. Race, education, and knowledge of bone marrow registry: indicators of willingness to donate bone marrow among African Americans and Caucasians. Transplant Proc 2005; 36:3212-9. [PMID: 15686731 DOI: 10.1016/j.transproceed.2004.10.019] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
BACKGROUND As bone marrow transplantation (BMT) increases, the availability of suitable donors becomes critical, especially for African Americans, who require a large donor pool to find a suitable match. Previous studies indicated willingness to donate marrow may be a barrier for achieving a large donor pool. METHODS We conducted a random-sample, statewide telephone survey of 421 Caucasians and 408 African Americans in South Carolina to determine if racial differences in willingness to donate bone marrow exist. We assessed a general level of willingness, asking, "Will you be willing to be a marrow donor?" We assessed an additional level of willingness, asking, "Are you willing to be contacted about bone marrow donation?" RESULTS We detected no racial differences in general willingness to donate (Caucasians 34%, African Americans 32%, P=.52), although there was a difference in willingness to be contacted to sign-up for the registry (Caucasians 18.3%, African Americans 11%, P=.003). African Americans were more aware that better matches occur within the same race (P <.0001). Caucasians were more knowledgeable about the registry (P <.0001). Younger, more highly educated respondents indicated a greater willingness to be donors. In both races, fear of pain was the most common reason for unwillingness to donate, and it was significantly higher in African Americans. CONCLUSION Our study suggests reported lack of general willingness does not explain the racial disparities in BMT. Many who expressed willingness to donate were not willing to be contacted to sign up for the registry, especially African Americans. Education and adequate pain control may improve minority recruitment.
Collapse
Affiliation(s)
- A A Onitilo
- Division of Hematology/Oncology, Department of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina 29414, USA.
| | | | | | | | | | | |
Collapse
|
8
|
Onitilo AA, Lazarchick J, Brunson CY, Frei-Lahr D, Stuart RK. Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc 2004; 35:3089-92. [PMID: 14697986 DOI: 10.1016/j.transproceed.2003.10.085] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
As the life expectancy of patients with homozygous sickle cell anemia (SCA) improves, SCA care providers are confronted with diseases of the adult SCA population rarely seen before. We report here a 40-year-old woman with SCA who developed diffuse large B-cell non-Hodgkin's lymphoma (NHL) that was treated with eight cycles of chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE), without complete remission. She subsequently underwent high-dose cyclophosphamide and total-body irradiation followed by autologous bone marrow transplantation (BMT). To reduce the risk of sickle cell crisis precipitated by G-CSF, she underwent hypertransfusion to maintain a low % hemoglobin S throughout her treatment course. Although she has required iron chelation therapy and shows no sign of modification of her underlying SCA, she remains in remission from NHL 12 years posttransplant. To our knowledge, this is the first reported case of autologous BMT in a patient with SCA. Our patient illustrates that SCA in itself does not preclude autologous stem cell transplantation for lymphoma in selected patients, and this report should encourage others to consider autologous BMT in adults with SCA where it represents a lifesaving therapy for malignant diseases.
Collapse
MESH Headings
- Adult
- Anemia, Sickle Cell/complications
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biopsy
- Bone Marrow Transplantation
- Female
- Humans
- Lymph Node Excision
- Lymph Nodes/pathology
- Lymphoma, B-Cell/complications
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/surgery
- Lymphoma, Large B-Cell, Diffuse/complications
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/surgery
- Neoplasm Staging
- Transplantation, Autologous
- Treatment Outcome
Collapse
Affiliation(s)
- A A Onitilo
- Department of Medicine, Hematology/Oncology Division, Medical University of South Carolina, 96 Jonathon Lucas Street, Charleston, SC 29425, USA
| | | | | | | | | |
Collapse
|